9
Feb
2026
Hike the High Sierras in August 2026 for Damon Runyon Cancer Research
Today I’m hiking on the highest mountain in Africa with 20 people who care deeply about alleviating suffering from cancer. Together, we’ve raised $1.2 million for cancer research. These resources will launch the careers of three young scientists in the US. We are forming deep, meaningful friendships on the trail. We are savoring the grandeur of Mother Nature, and the... Read More
9
Feb
2026
Gear Check: Timmerman Traverse for Damon Runyon Heads to Kilimanjaro
Gear check is when it starts getting fun and getting real. Our team of 21 hikers has arrived in Tanzania and gotten all our gear sorted. We’ll start the trek on Kilimanjaro Feb. 10. Then we spend the next seven days together on the trails to the top of the highest peak in Africa, elevation 19,341 feet / 5,895 meters.... Read More
5
Feb
2026
Eikon Goes Public, Generate Biomedicines Teed Up, & Sante Reloads
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2026
Eikon IPO on Deck, Biomarin Borrows Big, & Halozyme Rolls with the Surf
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
GSK Scoops Up RAPT, Genentech Bets on NC, & Relief for American Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
Helping People Lose Weight and Live Healthy: Ron Renaud on The Long Run
Ron Renaud is today’s guest on The Long Run. He is the CEO of Waltham, Mass.-based Kailera Therapeutics. Kailera is pursuing what could be the biggest opportunity in pharmaceutical industry history. It’s developing a portfolio of GLP-1-based drugs for obesity. Drugs in this category have been around a long time for treatment of Type 2 diabetes, but over the last... Read More
15
Jan
2026
Novo Rolls Out Wegovy Pill, Lilly Acquires Ventyx NLRP3, and Aktis Breaks IPO Ice
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2026
Following the Science to Immunology: Kate Haviland on The Long Run
Kate Haviland is today’s guest on The Long Run. Kate is the former CEO of Cambridge, Mass.-based Blueprint Medicines. Blueprint was one of the big biotech success stories of 2025. The company was acquired by Sanofi for $9.1 billion in cash at closing, and potentially $9.5 billion if certain milestones are met. The company started out with a vision for... Read More
6
Jan
2026
Timmerman Traverse for Damon Runyon Hits $1M Goal, Striving Toward Kilimanjaro
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has done it again. We have exceeded our team goal of raising $1 million for brilliant young cancer researchers around the US. We currently stand at $1,094,672. This team isn’t done. The latest group of 22 biotech executives and investors have one month left before traveling to Tanzania, banding together in common... Read More
6
Jan
2026
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2025
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
11
Dec
2025
5AM, OrbiMed Join $70M Bet on Prolynx Long-Lasting GLP-1 Weight Loss Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Dec
2025
PsiThera Gets $47.5M To Make Small Molecules Against TNF Superfamily
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2025
FDA Turmoil Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Merck Buys Cidara, Abbott Acquires Exact, & Function Flies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Building a Rare Disease Company: Neil Kumar on The Long Run
Neil Kumar is today’s guest on The Long Run. Neil is the founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma. BridgeBio got started a little more than 10 years ago with an idea of creating what it calls a “hub and spoke” business model for rare disease drug development. The hope was to find opportunities that were biologically compelling,... Read More
13
Nov
2025
Pfizer Grabs Metsera, Merck Delivers Oral PCSK9, & Kura Wins 1st FDA OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2025
Gate Bioscience Secures $65M To Turn Off Disease Proteins at the Source
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2025
Reinventing Drug Discovery with AI: Marc Tessier-Lavigne on The Long Run
Marc Tessier-Lavigne is today’s guest on The Long Run. Marc is the chairman and CEO of South San Francisco-based Xaira Therapeutics. Xaira is using computers to design protein drugs from scratch, building on work from co-founder David Baker’s lab at the University of Washington. Designing protein drugs on computers with ideal properties is a plenty big idea that won Baker... Read More